The Oncology Institute, Inc. STLN
3.62 USD -3.08 (-45.97%)
At closeNov 6, 2026, 7:18 PM EST
3.63 +0.01 +0.28%
After hours · Nov 6, 7:18 PM ET
3.35 Day range 6.43
2.38 52-week range 7.05
- YTD
- +1.69%
- 1 year
- -4.99%
News
benzinga.com B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10 B. Riley Securities analyst Yuan Zhi reiterates Starling Oncology (NASDAQ:STLN) with a Buy and lowers the price target from $11 to $10.
marketbeat.com Oncology Institute Q3 Earnings Call Highlights Oncology Institute NASDAQ: STLN, referred to as Starling Oncology by executives during its earnings call, reported a second consecutive quarter of positive adjusted EBITDA as specialty pharmacy…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10 BTIG analyst David Larsen maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $9 to $10.
benzinga.com Starling Oncology Q3 2026 Earnings Call Transcript Starling Oncology (NASDAQ:STLN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est Starling Oncology (NASDAQ:STLN) narrows FY2026 sales outlook from $650.000 million-$670.000 million to $650.000 million-$660.000 million vs $663.685 million estimate.
benzinga.com Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.05) by 160 percent. This is a 7.14 percent increase over losses of…- benzinga.com Needham Maintains Buy on Starling Oncology, Raises Price Target to $9 Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…- benzinga.com Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY Starling Oncology (NASDAQ:STLN) reported quarterly losses of $(0.08) per share. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…